Sumitomo treats first patient in Phase I/IIa trial of DSP-3077
The study will assess the tolerability and safety of two dose levels of DSP-3077 delivered via a single subretinal injection.
Analysis
View MoreAPIs to the rescue?
Oral bioavailability remains one of the biggest challenges in drug development, particularly for small-molecule APIs with poor solubility or permeability. Liam Critchley explores how pharmaceutical companies are using integrated formulation...
AI now: What QbD and PAT missed
Cool heads, smart chains
Sustainability vs suitability
Integrating sustainability compliance